Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
22 Feb 24
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
8 Jan 24
8-K
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
21 Dec 23
424B5
Prospectus supplement for primary offering
21 Dec 23
8-K
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
19 Dec 23
8-K
Other Events
15 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
6 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
8-K
Regulation FD Disclosure
7 Sep 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
3 Aug 23
8-K
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
20 Jun 23
8-K
Other Events
25 May 23
424B5
Prospectus supplement for primary offering
23 May 23
424B5
Prospectus supplement for primary offering
22 May 23
S-3ASR
Automatic shelf registration
22 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Guardant Health Reports First Quarter 2023 Financial Results
9 May 23
8-K
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
9 May 23
8-K
Guardant Health Announces Additions to Leadership Team
8 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Changes in Registrant's Certifying Accountant
10 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
2 Mar 23
8-K
Musa Tariq joins Guardant Health board of directors
27 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
23 Feb 23
8-K
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results
9 Jan 23
Latest ownership filings
4
Musa Tariq
16 Apr 24
4
John G. Saia
16 Apr 24
4
MYRTLE S POTTER
16 Apr 24
SC 13G
Deep Track Capital, LP
12 Apr 24
4
Meghan V. Joyce
5 Apr 24
4
John G. Saia
2 Apr 24
4
Kumud Kalia
2 Apr 24
4
Chris Freeman
2 Apr 24
4
CRAIG EAGLE
2 Apr 24
4
Darya Chudova
2 Apr 24
4
Steve E. Krognes
1 Apr 24
4
AmirAli Talasaz
1 Apr 24
4
Helmy Eltoukhy
1 Apr 24
4
AmirAli Talasaz
22 Mar 24
4
Helmy Eltoukhy
22 Mar 24
4
Kumud Kalia
19 Mar 24
4
Musa Tariq
18 Mar 24
4
MYRTLE S POTTER
18 Mar 24
4
Michael Brian Bell
18 Mar 24
4
Meghan V. Joyce
5 Mar 24
4
John G. Saia
4 Mar 24
4
Amelia Merrill
4 Mar 24
4
Kumud Kalia
4 Mar 24
4
Darya Chudova
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Steve E. Krognes
1 Mar 24
4
Terilyn J. Monroe
27 Feb 24
4
MYRTLE S POTTER
16 Feb 24
5
Helmy Eltoukhy
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Meghan V. Joyce
5 Feb 24
4
Steve E. Krognes
1 Feb 24
SC 13G
BAILLIE GIFFORD & CO
29 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
3
Terilyn J. Monroe
18 Jan 24
4
Darya Chudova
16 Jan 24
4
MYRTLE S POTTER
16 Jan 24
4
Michael Brian Bell
16 Jan 24